Medicines Co
Change company Symbol lookup
Select an option...
MDCO Medicines Co
YEXT Yext Inc
BOJA Bojangles Inc
DCOM Dime Community Bancshares Inc
BOX Box Inc
ONCE Spark Therapeutics Inc
CPB Campbell Soup Co
VSLR Vivint Solar Inc
CMTL Comtech Telecommunications Corp
SFM Sprouts Farmers Market Inc

Health Care : Pharmaceuticals | Small Cap BlendCompany profile

The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin). It also has a pipeline of products in development, including Carbavance, inclisiran and MDCO-700. Carbavance is used for the treatment of hospitalized patients with gram-negative bacterial infections. Inclisiran is used for the treatment of hypercholesterolemia. MDCO-700 includes sedative-hypnotic, which is used to induce and maintain sedation for procedural care and general anesthesia for surgical care. In addition to these products and products in development, it has a portfolio of generic drugs.

Day's Change
-0.625 (-3.16%)
B/A Size
Day's High
Day's Low
(Heavy Day)

Today's volume of 2,106,244 shares is on pace to be much greater than MDCO's 10-day average volume of 1,500,355 shares.




5 providers
Today's News, December 14, 2018
The Medicines Company Prices $150 Million of Convertible Notes

The Medicines Company (NASDAQ:MDCO) (the "Company") today announced that it has priced its private offering of $150 million in aggregate principal amount of its convertible senior notes due 2024. The notes will be sold only to...(BusinessWire)

December 12, 2018
The Medicines Company Announces Intention to Offer $150 Million of Convertible Notes

The Medicines Company (NASDAQ:MDCO) (the "Company") today announced that it proposes to offer $150 million aggregate principal amount of convertible senior notes due 2024, subject to market conditions and other factors. The...(BusinessWire)

December 11, 2018
The Medicines Company Appoints Mark Timney as Chief Executive Officer

The Medicines Company (NASDAQ: MDCO) today announced that its Board of Directors has appointed Mark Timney as the Company's new Chief Executive Officer and a member of the Board of Directors, effective immediately. Mr. Timney...(BusinessWire)

November 09, 2018
Company Profile for The Medicines Company

The Medicines Company is a biopharmaceutical company driven by an overriding purpose - to save lives, alleviate suffering and contribute to the economics of healthcare. The Company's goal is to create transformational solutions...(BusinessWire)

November 08, 2018
The Medicines Company Reports Third-Quarter 2018 Results

The Medicines Company (NASDAQ:MDCO) today reported its financial results for the third quarter ended September 30, 2018. "During the third quarter of 2018, we continued to advance inclisiran through Phase III trials and other, key...(BusinessWire)

November 05, 2018
Report: Exploring Fundamental Drivers Behind SkyWest, Blueprint Medicines, HP, Hewlett Packard Enterprise, Cardinal Health, and The Medicines -- New Horizons, Emerging Trends, and Upcoming Developments

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of SkyWest, Inc. (NASDAQ:SKYW), Blueprint Medicines Corporation...(Globe Newswire)

November 01, 2018
The Medicines Company to Announce Third-Quarter 2018 Financial Results on November 8

The Medicines Company (NASDAQ:MDCO) will host a conference call and audio webcast on Thursday, November 8, 2018, at 8:30 a.m., EST, to discuss its third-quarter 2018 financial results and operational developments. (BusinessWire)

October 15, 2018
Investor Expectations to Drive Momentum within Fossil Group, The Medicines, BWX Technologies, PVH, Group 1 Automotive, and Assurant -- Discovering Underlying Factors of Influence

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Fossil Group, Inc. (NASDAQ:FOSL), The Medicines Company (NASDAQ:MDCO)...(Globe Newswire)

October 01, 2018
The Medicines Company Announces Recommendation by Independent Data Monitoring Committee to Continue Inclisiran Phase III Trials Following Fourth Review of Unblinded Data

---At the time of IDMC review, substantially all patients in Phase III trials had received two doses, and more than 648 patients had received their third dose of inclisiran or placebo- ---Phase III trials of inclisiran progressing as planned with no...(BusinessWire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2018 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2018. All rights reserved.